Concordia Healthcare Corp. announces FDA agreement on Special Protocol Assessment for Phase 3 Clinical trial on new therapy to treat perihilar cholangiocarcinoma ” TSX:CXR ) announced today that its subsidiary Pinnacle Biologics, Inc. , a biopharmaceutical research and development company specializing in rare diseases, has reached an agreement with … (more)
Source: www.topix.com Via newsmixx: home News